Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients - yes, but how?

Clinical Neuropathology

Volumn 31, Issue 6, 2012, Pages 405-408

  Berghoff, Anna S ^a,c   Preusser, Matthias ^b,c  

^a Institute of Neurology   (Australia)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Comprehensive Cancer Center Vienna CNS Tumors Unit ^*  (Australia)

Author keywords

Analytical performance; Clinical performance; Glioblastoma; MGMT

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL DECISION MAKING; DOSE DENSIFICATION; GLIOBLASTOMA; HEALTH CARE COST; HUMAN; MULTIMODALITY CANCER THERAPY; PATIENT CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; AGED; BRAIN TUMOR; DNA METHYLATION; GENETIC PROCEDURES; GENETICS; PRACTICE GUIDELINE; PROGNOSIS; PROMOTER REGION; STANDARD;

AGED; BRAIN NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GENETIC TECHNIQUES; GLIOBLASTOMA; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84876353208     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/NP300576     Document Type: Article

References (18)

1. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004; 4: 296-307. doi:10.1038/nrc1319 PubMed
2. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997-1003. doi:10.1056/NEJMoa043331 PubMed
3. Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998; 16: 3851-3857. PubMed
4. Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O, Westphal M, Wick W, Pietsch T, Loeffler M, Weller M; for the German Glioma Network. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer. 2012; 131: 1342-1350. doi:10.1002/ijc.27385 PubMed
5. Brandes AA, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V, Bacci A, Agati R, Calbucci F, Ermani M. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer. 2009; 115: 3512-3518. doi:10.1002/cncr.24406 PubMed
6. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 2009; 27: 5743-5750. doi:10.1200/JCO.2009.23.0805 PubMed
7. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10: 459-466. doi:10.1016/S1470- 2045(09)70025-7 PubMed
8. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996. doi:10.1056/NEJMoa043330 PubMed
9. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M; NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012; 13: 707-715. doi:10.1016/S1470-2045(12)70164-X PubMed
10. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008; 9: 29-38. doi:10.1016/S1470-2045(07)70384-4 PubMed
11. Holdhoff M, Ye X, Blakeley JO, Blair L, Burger PC, Grossman SA, Diaz LA Jr. Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. Journal of neuro-oncology. 2012.
12. Preusser M, Elezi L, Hainfellner JA. Reliability and reproducibility of PCR-based testing of O6- methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin- fixed and paraffin-embedded neurosurgical biopsy specimens. Clin Neuropathol. 2008; 27: 388-390. PubMed
13. Yip S, Iafrate AJ, Louis DN. Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J Neuropathol Exp Neurol. 2008; 67: 1-15. doi:10.1097/nen.0b013e318 15f65fb PubMed
14. Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R; for the Nordic Clinical Brain Tumour Study Group (NCBTSG). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012; 13: 916-926. doi:10.1016/S1470-2045(12)70265-6 PubMed
15. Rodriguez FJ, Thibodeau SN, Jenkins RB, Schowalter KV, Caron BL, O'neill BP, James CD, Passe S, Slezak J, Giannini C. MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol. 2008; 16: 59-65. PubMed
16. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010; 6: 39-51. doi:10.1038/nrneurol.2009.197 PubMed
17. Preusser M, Plumer S, Dirnberger E, Hainfellner JA, Mannhalter C. Fixation of brain tumor biopsy specimens with RCL2 results in well-preserved histomorphology, immunohistochemistry and nucleic acids. Brain Pathol. 2010; 20: 1010-1020. doi:10.1111/j.1750-3639.2010.00400.x PubMed
18. Vonthein R, Ziegler A. On the Use of the Terms Repeatability and Reproducibility Regarding "Reproducibility of genotypes as measured by the Affymetrix GeneChip(R) 100K Human Mapping Array Set" by Fridley and colleagues (2008). Comput Stat Data Anal. 2009; 52: 5367-5374.